A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 28 Sep 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2010-091-000430).
- 18 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History